Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Solid Biosciences (SLDB) over the last 3 years, with Q1 2022 value amounting to $6.2 million.

  • Solid Biosciences' Current Deferred Revenue fell 4213.09% to $6.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $6.2 million, marking a year-over-year decrease of 4213.09%. This contributed to the annual value of $8.1 million for FY2021, which is 6100.01% down from last year.
  • Solid Biosciences' Current Deferred Revenue amounted to $6.2 million in Q1 2022, which was down 4213.09% from $8.1 million recorded in Q4 2021.
  • Solid Biosciences' Current Deferred Revenue's 5-year high stood at $20.7 million during Q4 2020, with a 5-year trough of $6.2 million in Q1 2022.
  • Over the past 3 years, Solid Biosciences' median Current Deferred Revenue value was $9.5 million (recorded in 2021), while the average stood at $10.8 million.
  • As far as peak fluctuations go, Solid Biosciences' Current Deferred Revenue crashed by 6100.01% in 2021, and later crashed by 4213.09% in 2022.
  • Over the past 3 years, Solid Biosciences' Current Deferred Revenue (Quarter) stood at $20.7 million in 2020, then crashed by 61.0% to $8.1 million in 2021, then decreased by 23.64% to $6.2 million in 2022.
  • Its Current Deferred Revenue stands at $6.2 million for Q1 2022, versus $8.1 million for Q4 2021 and $8.9 million for Q3 2021.